SOXL ranks 4th and LABU 11th of 30 funds in the 3x Leveraged Long Category.
LABU vs SOXL
4.7%by weight
SOXL −0.21pt a year
0.96%0.75%
SOXL 170.5×the volume
415K70.7M
SOXL +47.3pt
−7.9%+39.4%
LABU vs SOXL Performance
−76.4%+66.7%
- LABU 0.96%
- SOXL 0.75%, better
- LABU $673M
- SOXL $24.3B
- LABU +89.6%, better
- SOXL +61.4%
- LABU 0.37%, better
- SOXL 0.12%
- LABU 168
- SOXL 43
- LABU 415K sh
- SOXL 70.7M sh, better
- LABU $256.47
- SOXL $102.45
ETF.net Grade
| Pillar | LABU | SOXL |
|---|---|---|
| Cost | B62 | A100Higher |
| Mission | ||
| Risk | C45Higher | D32 |
| Tradability | C49 | A79Higher |
| Holdings | ||
| Durability | B59 | B69Higher |
Rank among 3x Leveraged Long funds
Same Category. LABU and SOXL are both graded against the same 30 3x Leveraged Long funds, so their Grades compare head to head.
Our read on each fund
LABUB
SOXLA
In short
LABU Three times the daily move of an index of roughly 160 biotech stocks, the corner of the market where one trial readout resets the tape. Direxion's 2015-vintage bull leg, with a bear twin wired to the same benchmark.
SOXL A 3x bet on chip stocks that resets every single day. Direxion launched it in 2010, long before AI made semiconductors the market's main event, and it is now one of the most heavily traded leveraged funds out there.
Stated mandate
LABU The fund seeks daily investment results, before fees and expenses, equal to 300% of the performance of the S&P Biotechnology Select Industry Index.
SOXL It is designed to deliver a daily result three times the performance of the NYSE Semiconductor Index, before fees and expenses, with the objective applying for a single day.
Why people hold it
Worth knowing
LABU vs SOXL Holdings
How LABU and SOXL differ
4.7%
Shared holdings make up 9.6% of LABU and 8.4% of SOXL.
Level by level
- Asset class0.0%
- Sector0.0%
- Holdings4.7%
- Country89.8%
Sector
| Sector | More in LABUMore in SOXL | LABU | SOXL |
|---|---|---|---|
| Technology | SOXL +100.0 points | 0.0% | 100.0% |
| Health Care | LABU +99.3 points | 99.3% | 0.0% |
| Financials | LABU +0.7 points | 0.7% | 0.0% |
Country, concentration and asset class
Country
| Country | More in LABUMore in SOXL | LABU | SOXL |
|---|---|---|---|
| United States | LABU +6.0 points | 95.3% | 89.3% |
| Taiwan | SOXL +4.7 points | 0.0% | 4.7% |
| South Korea | SOXL +3.0 points | 0.0% | 3.0% |
| Ireland | LABU +1.5 points | 1.5% | 0.0% |
| Switzerland | LABU +1.4 points | 1.4% | 0.0% |
| United Kingdom | LABU +1.3 points | 1.3% | 0.0% |
| Israel | SOXL +1.1 points | 0.0% | 1.1% |
| Netherlands | SOXL +1.0 points | 0.5% | 1.5% |
| Singapore | SOXL +0.4 points | 0.0% | 0.4% |
Concentration
- LABU80.2%
- SOXL74.3%
- LABU159
- SOXL32
Asset class
- LABU
- Leveraged/Inverse
- SOXL
- Equity
Holdings
- Only in LABU158
- In both1
- Only in SOXL31
Only in LABU
158 securities, 20.2% of LABU by weight
- Moderna Inc0.48%
- Twist Bioscience Corp0.40%
- Natera Inc0.38%
- Halozyme Therapeutics Inc0.35%
- Biogen Inc0.34%
- Amgen Inc0.34%
- United Therapeutics Corp0.34%
- AbbVie Inc0.34%
- Spyre Therapeutics Inc0.33%
- Gilead Sciences Inc0.33%
- Exelixis Inc0.33%
- Tg Therapeutics Inc0.31%
- Grail Inc0.31%
- Oruka Therapeutics Inc0.31%
- Vertex Pharmaceuticals Inc0.30%
- Regeneron Pharmaceuticals0.29%
- Alkermes PLC0.29%
- Crispr Therapeutics AG0.29%
- Protagonist Therapeutics Inc0.29%
- Ptc Therapeutics Inc0.28%
- Neurocrine Biosciences Inc0.27%
- Krystal Biotech Inc0.27%
- Bridgebio Pharma Inc0.27%
- Incyte Corp0.27%
- Revolution Medicines Inc0.27%
- Roivant Sciences Ltd0.26%
- Biomarin Pharmaceutical Inc0.26%
- Kymera Therapeutics Inc0.26%
- Kodiak Sciences Inc0.25%
- Insmed Inc0.25%
- Cytokinetics Inc0.25%
- Erasca Inc0.25%
- Cogent Biosciences Inc0.24%
- Vaxcyte Inc0.24%
- Praxis Precision Medicines I0.24%
- Veracyte Inc0.24%
- Ionis Pharmaceuticals Inc0.23%
- Madrigal Pharmaceuticals Inc0.23%
- Dianthus Therapeutics Inc0.22%
- Travere Therapeutics Inc0.22%
- Rhythm Pharmaceuticals Inc0.22%
- Arrowhead Pharmaceuticals In0.21%
- Iovance Biotherapeutics Inc0.21%
- Mirum Pharmaceuticals Inc0.21%
- Immunitybio Inc0.20%
- Alnylam Pharmaceuticals Inc0.20%
- Beam Therapeutics Inc0.19%
- Cg Oncology Inc0.19%
- Arcutis Biotherapeutics Inc0.19%
- Caredx Inc0.19%
Only in SOXL
31 securities, 23.4% of SOXL by weight
- Jp Morgan 100 Us Trsy Capital 31632.46%
- Advanced Micro Devices1.99%
- Intel Corp1.70%
- Micron Technology Inc1.61%
- NVIDIA Corp1.60%
- Broadcom Inc1.54%
- Texas Instruments Inc0.99%
- Analog Devices Inc0.99%
- Qualcomm Inc0.90%
- Marvell Technology Inc0.85%
- Kla Corp0.79%
- Nxp Semiconductors NV0.77%
- Applied Materials Inc0.76%
- Lam Research Corp0.70%
- Taiwan Semiconductor-Sp Adr0.66%
- Monolithic Power Systems Inc0.65%
- Sk Hynix Inc-Adr0.62%
- Teradyne Inc0.53%
- Microchip Technology Inc0.49%
- Astera Labs Inc0.47%
- On Semiconductor0.33%
- Credo Technology Group Holdi0.32%
- Asml Holding Nv-Ny Reg Shs0.31%
- Entegris Inc0.28%
- Tower Semiconductor Ltd0.23%
- Ase Technology Holding -Adr0.21%
- Macom Technology Solutions H0.21%
- Cerebras Systems Inc - A0.13%
- United Microelectron-Sp Adr0.12%
- Arm Holdings Plc-Adr0.09%
- Stmicroelectronics Nv-Ny Shs0.09%
Weight gaps
All 1 Holdings in both funds, largest gap first.
| Holding | More in LABUMore in SOXL | LABU | SOXL |
|---|---|---|---|
| Goldman Finl Sq Trsry Inst 506 | LABU +3.53 points | 5.47% | 1.94% |
How we measure overlap
Each holding counts at its smaller weight in the two funds, summed over the full Holdings. Sector, country and asset class use the same rule on each fund’s split. Cash, FX and derivative lines stay out of the counts. Two bond funds get no overlap figure.
LABU vs SOXL Cost
Overpaying LABU vs SOXL
$3,552
On $10,000 over 30 years. 7% growth a year before fees, expense ratio only.
LABU 0.96%
$18,034
SOXL 0.75%
$14,482
Cost over time
Year by year
| Year | LABU | SOXL | Overpaying |
|---|---|---|---|
| 10 | $1,695 | $1,336 | $359 |
| 20 | $6,383 | $5,078 | $1,305 |
| 30 | $18,034 | $14,482 | $3,552 |
- 0.96%LABU
- 0.75%SOXL, cheaper
- Middle half of 3x Leveraged Long funds
- Median 0.96%
SOXL cheapest of 30 funds
LABU 11th cheapest of 30 funds
LABU vs SOXL Dividends
- LABU 0.37%, better
- SOXL 0.12%
- LABU $0.91
- SOXL $0.09
- LABU $0.91
- SOXL $0.09
- LABU Dec 23, 2025
- SOXL Sep 22, 2026
- LABU Dec 31, 2025
- SOXL Sep 29, 2026
- LABU Quarterly
- SOXL Annual
Distribution history
LABU vs SOXL Risk
Fall from peak · 5 years
- LABU
- SOXL
Risk facts
- Volatility
- LABU 76.7%, betterSOXL 137.2%
- Return per unit of risk
- LABU 0.96, betterSOXL 0.90
- Worst fall
- LABU −97.1%SOXL −90.5%, better
- Market sensitivity
- LABU 3.16SOXL 7.64
LABU and SOXL in the news
Popular comparisons
- 0.96% · 0.78%
- Same Category. Both funds are graded against the same funds, so their Grades compare head to head.
- 0.75% · 0.78%
- Same Category. Both funds are graded against the same funds, so their Grades compare head to head.
- 0.96% · 0.94%
- Same Category. Both funds are graded against the same funds, so their Grades compare head to head.
- 0.75% · 0.94%
- Same Category. Both funds are graded against the same funds, so their Grades compare head to head.
- 0.96% · 0.88%
- Same Category. Both funds are graded against the same funds, so their Grades compare head to head.
- 0.75% · 0.88%
- Same Category. Both funds are graded against the same funds, so their Grades compare head to head.
